Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: CorMedix Inc.

Market Cap 686M 592M 546M 511M 957M 65.17B 972M 6.44B 2.51B 31.72B 2.57B 2.52B 110B P/E Ratio 2026 *
17.5x
P/E Ratio 2027 * 102x
Enterprise Value 630M 544M 502M 470M 880M 59.91B 894M 5.92B 2.31B 29.16B 2.37B 2.32B 101B EV / Sales 2026 *
1.89x
EV / Sales 2027 * 2.01x
Free-Float
92.49%
Yield 2026 *
-
Yield 2027 * -
1 day-2.46%
1 week+4.55%
Current month+3.55%
1 month+10.21%
3 months+35.50%
6 months-23.93%
Current year-24.85%
1 week 8.46
Extreme 8.46
9.09
1 month 7.52
Extreme 7.52
9.09
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
17.43
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-09
Director of Finance/CFO 54 2025-08-28
Chief Tech/Sci/R&D Officer - 2021-12-31
Director TitleAgeSince
Director/Board Member 67 2015-08-05
Chairman 81 2017-08-02
Director/Board Member 70 2011-08-15
Date Insider Type Main position Quantity % Market Cap.
02-03Free

Chief Executive Officer

77,156 0.0979%
02-03Free

Chief Operating Officer

36,006 0.0457%
02-03Free

General Counsel

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
-2.46%+4.55%-39.97%+60.37% 686M
-1.42%-1.44%+45.70%+9.56% 294B
-1.59%-2.63%+16.07%-20.76% 67.08B
-1.74%-2.84%+28.75%+110.80% 8.24B
+0.87%+2.39%-3.08%-10.49% 7.84B
-0.68%-0.23%-2.66%+9.74% 4.54B
+1.05%-0.39%-27.51%+36.69% 3.8B
+2.01%+10.19%-14.95%+9.40% 3.35B
-2.50%-0.76%+38.65%+31.35% 2.58B
+3.11%+1.30%+5.67%-21.79% 1.98B
Average -0.34%+3.01%+4.67%+21.49% 39.41B
Weighted average by Cap. -1.34%-1.23%+37.16%+6.46%

Financials

2026 *2027 *
Net sales 334M 289M 266M 249M 466M 31.76B 474M 3.14B 1.22B 15.46B 1.25B 1.23B 53.52B 285M 246M 227M 212M 398M 27.09B 404M 2.68B 1.04B 13.19B 1.07B 1.05B 45.66B
Net income 46.78M 40.4M 37.23M 34.85M 65.31M 4.45B 66.32M 440M 171M 2.16B 176M 172M 7.49B 8.47M 7.32M 6.74M 6.31M 11.83M 805M 12.01M 79.63M 31.05M 392M 31.8M 31.12M 1.36B
Net Debt -55.39M -47.84M -44.09M -41.27M -77.34M -5.27B -78.54M -521M -203M -2.56B -208M -203M -8.87B -113M -97.55M -89.89M -84.15M -158M -10.74B -160M -1.06B -414M -5.23B -424M -415M -18.09B
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
26-06-12 8.740 $ -2.46% 969,813
26-06-11 8.960 $ +2.17% 1,237,932
26-06-10 8.770 $ +1.39% 1,317,079
26-06-09 8.650 $ +1.29% 1,412,758
26-06-08 8.540 $ +2.15% 1,773,860
Trader
Investor
Global
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
8.740USD
Average target price
15.20USD
Spread / Average Target
+73.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!